Browsing Medicina Experimental by Subject "Olomoucine"
Now showing items 1-4 of 4
-
BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis
(American Association for Cancer Research, 2008)In previous reports we have shown in SH-SY5 cells that Olomoucine and Roscovitine, two inhibitory drugs of Cyclin Dependent Kinases, caused apoptosis independent of the extrinsic pathway. In this experimental paradigm, ... -
Caspase 8/10 are not mediating apoptosis in neuroblastoma cells treated with CDK inhibitory drugs
(Elsevier, 2005)Olomoucine and Roscovitine are pharmacological inhibitors of cyclin-dependent kinases (CDK) displaying a promising profile as anticancer agents. Both compounds are effective inductors of apoptosis in a human neuroblastoma ... -
Cell differentiation, caspase inhibition and macromolecular synthesis blockage, but not Bcl-2 or Bcl-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two cdk inhibitory drugs.
(Elsevier, 2004)Olomoucine and Roscovitine are two ATP-competing compounds described as specific inhibitors of cyclin-dependent kinases (CDK). Both drugs showed to induce apoptosis in SH-SY5Y, a neuroblastoma-derived cell line. In these ... -
Trancriptional modulation of apoptotis regulators by Roscovitine and related compounds
(Springer Science Business Media, 2011)Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs in thecontext of new cancer therapies. Roscovitine and related compounds, like seliciclib and olomoucine, are effective inducers ...